Abstract 166P
Background
Gallbladder (GB) cancer shows high prevalence in South Korea, and tends to show high fatality. In surgically fit patients, radical resection aiming an R0 margin combined with lymphadenectomy is the mainstay of curative-intent therapy. In spite of R0 resection, however, high recurrence rate is observed in GB cancer, demanding a need to figure out risk factors related to recurrence after surgery.
Methods
This is a single center, retrospective cohort study conducted on 148 patients with GB cancer who underwent R0 resection between January 1st, 2014 and December 31st, 2019. Several variables were analyzed with statistical tools to identify risk factors related to prognosis. Early recurrence, defined as progression of disease within one year after R0 resection, was studied with logistic regression analysis.
Results
Early recurrence was observed in 15.5% (N=23) of patients. Based on statistical analysis, independent risk factors of early recurrence were age over 65 (hazard ratio [HR] 4.44, 95% confidence interval [CI] 1.25 - 15.75, p=0.021), glycated hemoglobin (HbA1c) level more than 6.5% (HR 5.00, 95% CI 1.37 – 18.31, p=0.015), surgical T stage more than T3 (HR 16.76, 95% CI 5.76 – 48.73, p<0.001), surgical N stage more than N1 (HR 5.82, 95% CI 2.22 – 15.28, p<0.001), pathologic differentiation of moderate to poor differentiation (HR 5.20, 95% CI 1.64 – 16.48, p=0.005), reversed albumin-globulin ratio (HR 0.08, 95% CI 0.01 – 0.45, p=0.004), high c-reactive protein (CRP) level (HR 1.22, 95% CI 1.08 – 1.38, p=0.001), and high carbohydrate antigen (CA) 19-9 level (HR 3.53, 95% CI 1.36 – 9.13, p=0.009). Table: 166P
Variable | Univariate analysis | ||
OR | 95% CI | P | |
Age (≥ 65 vs < 65) | 4.44 | (1.25 - 15.75) | .021 |
Sex (male vs female) | 0.86 | (0.34 - 2.17) | .743 |
Smoking (yes vs no) | 1.02 | (0.27 - 3.83) | .974 |
Alcohol (yes or no) | 0.76 | (0.24 - 2.44) | .649 |
HbA1C (≥ 6.5 vs < 6.5) | 5.00 | (1.37 - 18.31) | .015 |
Surgical T stage (T3 + T4 vs T1 + T2) | 16.76 | (5.76 - 48.73) | <.001 |
Surgical N stage (N1 + N2 vs N0) | 5.82 | (2.22 - 15.28) | <.001 |
Pathology differentiation (non-well vs well) | 5.20 | (1.64 - 16.48) | .005 |
WBC | 0.99 | (0.89 - 1.10) | .875 |
AST | 1.00 | (1.00 - 1.00) | .728 |
ALT | 1.00 | (1.00 - 1.01) | .653 |
Bilirubin | 1.05 | (0.90 - 1.23) | .549 |
Albumin-globulin ratio (≥ 1.0 vs < 1.0) | 0.08 | (0.01 - 0.45) | .004 |
CRP | 1.22 | (1.08 - 1.38) | .001 |
CA19-9 (≥ 39.0 vs < 39.0) | 3.53 | (1.36 - 9.13) | .009 |
Conclusions
Advanced pathologic stage and high inflammatory marker levels, reflecting high tumor burden, were related with poor surgical outcome. Interestingly, high HbA1c level was connected with early recurrence as well. In conclusion, active screening for early detection, reducing inflammatory conditions, and managing diabetes might reduce early recurrence after R0 resection of GB cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pusan National University Hospital.
Funding
This work was supported by clinical research grant from Pusan National University in 2023.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract